Breaking the serologic rule: chronic hepatitis B with simultaneous HBsAg and anti-HBs positivity—a case report Authors: Ghada Mohamed Balah, Mohammed Salmen Bazuqamah, Eslam Ahmed Helal, Mohammad Aly Moharram, Hend Masoud Masoud, Amira Abdelfatah Soliman, Ali Ismail Yahya Published: 2026 ABSTRACT AbstractBackgroundChronic hepatitis B virus (HBV) infection continues to pose a significant global disease burden, because of its potential progression to liver cirrhosis and hepatocellular carcinoma (HCC). Worldwide, more than 250 million individuals are estimated to be living with chronic HBV infection. Under standard serologic interpretation, the presence of hepatitis B surface antigen (HBsAg) signifies ongoing infection, whereas antibodies to hepatitis B surface antigen (anti-HBs) are generally associated with viral clearance or protective immunity. The simultaneous presence of both markers is rare and may lead to misinterpretation of serologic results, particularly when identified incidentally during routine screening in a primary care settings.Case presentationWe describe a 60-year-old Saudi woman with an asymptomatic chronic HBV infection incidentally identified during routine pre-colonoscopy screening in a primary care setting. Laboratory testing revealed reactive HBsAg, total anti-HBc positivity, reactive anti-HBs titer, and HBV DNA level was 275 IU/mL consistent with low-level viremia. Liver enzymes were mildly elevated on prior testing subsequently normalized on follow- up. Transient elastography demonstrated no evidence of hepatic fibrosis or steatosis. The patient had no history of HBV vaccination, blood transfusions, liver disease, or recognized high-risk exposures, including intravenous drug use or high-risk sexual or household contact.ConclusionThis case highlights a diagnostic pitfall in HBV serology, as concurrent HBsAg and anti-HBs positivity does not indicate viral clearance and may reflect immune escape mutations, viral heterogeneity, or host immune factors. Recognition of this rare serologic profile is particularly important for primary care physicians, as accurate interpretation requires integration of serologic, virologic, and clinical data, particularly in asymptomatic patients identified through routine screening. This ensure appropriate diagnosis, long-term surveillance, and risk stratification. Clinicians should remain vigilant when encountering this rare serologic profile to guide appropriate referral and follow-up.Keywords: Chronic hepatitis B, HBsAg, Anti-HBs, Concurrent HBsAg and anti-HBs, Diagnostic pitfall, Hepatitis B virus DNA, Case report Background Globally, chronic HBV infection affects hundreds of millions of individuals and remains a leading cause of liver-related morbidity and mortality, that represents a substantial public health challenge, with outcomes spanning from acute self-limiting infection to chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). These outcomes are largely determined by the interplay between viral factors and the host immune response [1]. Typically, active HBV infection is indicated by the presence of hepatitis B surface antigen (HBsAg) in the blood, whereas the development of neutralizing antibodies against HBsAg (anti-HBs) generally signifies resolution of infection, either spontaneously or following antiviral therapy, or immunity acquired through vaccination [2]. In rare instances, HBsAg and anti-HBs coexist simultaneously, creating a paradoxical serologic profile that poses diagnostic and clinical challenges, particularly when identified incidentally during routine screening in asymptomatic individuals [3, 4]. This unusual pattern may result from immune escape variants, viral mutations, infection with heterologous HBV subtypes, or altered host immune responses [3, 5]. Among patients with chronic hepatitis B (CHB), the coexistence of HBsAg and anti-HBs has been associated with an increased risk of HCC and may influence disease progression and long-term prognosis. This pattern is associated with a higher incidence of HCC, with one study showing a 5-year cumulative incidence of 12.7% in the coexistence group versus 4.9% in those with HBsAg alone [6, 7]. We report the case of a 60-year-old anasymptomatic woman with chronic HBV infection incidentally identified during routine pre-procedural screening, demonstrating concurrent positivity for HBsAg and anti-HBs, to highlight this diagnostic challenge and discuss its potential mechanisms and clinical implications of this rare serologic pattern for both frontline and specialist clinicians. Case presentation A 60-year-old Saudi woman presented to the outpatient department at King Khalid Hospital, Najran, with intermittent, nonspecific abdominal pain. She had no symptoms suggestive of acute hepatitis or liver disease. She denied HBV vaccination, blood transfusions, intravenous drug use, high-risk sexual behavior, alcohol consumption, or immunosuppressive therapy, confirming no identifiable high-risk exposures. During a routine primary care visit for colorectal cancer screening, a fecal immunochemical test (FIT) was positive, prompting referral for colonoscopy. Colonoscopic evaluation revealed no significant abnormalities, and histopathologic examination demonstrated no evidence of dysplasia or malignancy. Routine pre-procedural laboratory investigations revealed the following results: ALT 22 U/L (normal 1–34), AST 22 U/L (normal 1–34), alkaline phosphatase 143 U/L (normal 30–120), GGT 15 U/L (normal 1–37), total bilirubin 59.2 µmol/L (normal 5–21), direct bilirubin 9.4 µmol/L (normal 0–3.39), and albumin 37 g/L (normal 35–52). Three months prior, mild elevations were noted: ALT 56 U/L, AST 60 U/L, ALP 127 U/L, GGT 12 U/L, total bilirubin 49.4 µmol/L, direct bilirubin 10.1 µmol/L, and albumin 33 g/L (Table 1). Table 1Laboratory findings of the patientParameters3 months before colonoscopyPre-colonoscopy4 months follow upReference rangeALT56 U/L22 U/L17 U/L1–34 U/LAST60 U/L22 U/L22 U/L1–34 U/LALP127 U/L143 U/L142 U/L30–120 U/LGGT12 U/L15 U/L18 U/L1–37 U/LTotal bilirubin49.4 µmol/L59.2 µmol/L55.1 µmol/L5–21 µmol/LDirect bilirubin10.1 µmol/L9.4 µmol/L8.8 µmol/L0–3.39 µmol/LAlbumin33 g/L37 g/L42 g/L35–52 g/LAST Aspartate Aminotransferase, ALT alanine aminotransferase, GGT gamma-glutamyl transferase, ALP Alkaline phosphataseBold text indicates abnormal values Laboratory findings of the patient AST Aspartate Aminotransferase, ALT alanine aminotransferase, GGT gamma-glutamyl transferase, ALP Alkaline phosphatase Bold text indicates abnormal values Serologic testing using a chemiluminescence immunoassay showed reactive HBsAg, reactive anti-HBs titer (11.2 mIU/mL; reference range: reactive ≥ 10 mIU/mL), total anti-HBc positivity, and non-reactive anti-HBc IgM. Hepatitis C virus antibodies were negative. Quantitative HBV DNA polymerase chain reaction (PCR) demonstrated low-level viremia at 275 IU/mL. The assay detection limit was 20 IU/mL, confirming that the observed level reflects low but detectable viral replication (Table 2). Table 2Key diagnostic tests (pre-colonoscopy)TestResultReference/InterpretationHBsAgReactiveIndicates ongoing infectionAnti-HBs11.2 mIU/mLLow-titer positivity (≥ 10 mIU/mL reactive)Total anti-HBcReactiveConfirms prior exposureAnti-HBc IgMNon-reactiveNo acute infectionHBV DNA275 IU/mLLow-level viremia (detection limit 20 IU/mL)FibroScan3.0 kPa/CAP 100 dB/mNo fibrosis or steatosis Key diagnostic tests (pre-colonoscopy) Abdominal ultrasonography revealed a post-cholecystectomy status with otherwise normal hepatic and biliary anatomy, no focal lesions, and no evidence of ascites or lymphadenopathy. Transient elastography (FibroScan®) demonstrated a liver stiffness measurement of 3.0 kPa (F0, indicating no fibrosis) and a controlled attenuation parameter (CAP) of 100 dB/m (S0, indicating no steatosis), with an interquartile range (IQR) of 30%, consistent with acceptable scan reliability (Table 2). Based on serologic and virologic findings, a diagnosis of chronic hepatitis B infection with the atypical coexistence of HBsAg and anti-HBs was established. Antiviral therapy was deferred due to low-level viremia and normal liver function, she was referred to hepatology for further evaluation, including consideration of HBV genotyping and long-term monitoring. A follow-up plan was established: routine monitoring in hepatology clinic every 6–12 months, including assessment of liver enzymes, HBV DNA, and HBsAg/anti-HBs levels, as well as surveillance for fibrosis progression and hepatocellular carcinoma. This case highlights the incidental detection of chronic hepatitis B in a primary care setting, illustrating how routine pre-procedural screening can uncover atypical serologic patterns. It underscores the importance of clinician awareness regarding low-level viremia and the need for careful interpretation of HBV serology, particularly in asymptomatic patients without known risk factors. TimelineTime pointClinical event3 months priorMild elevation of ALT, AST, and bilirubin detected on routine laboratory testingScreening visitPositive fecal immunochemical test (FIT)Pre-colonoscopy evaluationHBsAg positive, anti-HBs positive (11.2 mIU/mL), HBV DNA 275 IU/mLImagingAbdominal ultrasound normal; FibroScan showed F0 fibrosis and S0 steatosisCurrent statusNormal liver enzymes; referred to hepatology for monitoring4 months follow upNormal ALT/AST, AFP within normal range; abdominal ultrasound showed no focal hepatic lesions or ascites Timeline Follow-up and outcomes The patient remains clinically stable under regular hepatology follow-up, with normal liver enzyme levels and there is no clinical evidence of hepatic decompensation or disease progression. At 4 months of follow-up, repeat laboratory evaluation showed normal transaminases (ALT 17 U/L, AST 21 U/L), with mildly elevated total bilirubin (55.1 µmol/L) and alkaline phosphatase (142 U/L) [Table 1]. Alpha-fetoprotein was within normal limits 2.2 ng/mL (normal: 0–9). Follow-up abdominal ultrasonography demonstrated a liver of normal size and echotexture, without focal lesions, biliary dilatation, ascites, or abnormal portal vein caliber. These findings indicate ongoing biochemical and radiologic stability. The patient continues routine surveillance for chronic hepatitis B and hepatocellular carcinoma (HCC), Discussion The coexistence of HBsAg and anti-HBs represents a paradoxical serologic pattern that challenges the conventional interpretation of hepatitis B virus (HBV) infection [6, 8]. Although traditionally considered mutually uncommon, this phenomenon is increasingly recognized in clinical practice and may be underappreciated during routine screening, particularly in a primary care setting. Conventionally, the presence of HBsAg denotes active viral replication, although anti-HBs is considered a marker of recovery or vaccine-induced immunity [9, 10]. Their simultaneous presence suggests complex interactions between viral characteristics and host immune responses and carries important diagnostic and clinical implications [3]. The prevalence of concurrent HBsAg and anti-HBs positivity may reach up to 4.2% in certain populations, with considerable geographic variation. Reported prevalence ranges from 2.4 to 5.8% in China, 2.9–7.0% in South Korea, 5.0–8.9% in France, and 0.2–3.6% in Turkey [11, 12]. Previous studies have further shown that individuals with concurrent anti-HBs positivity tend to be older, have lower platelet counts, and demonstrate a higher prevalence of hepatitis B e antigen (HBeAg) positivity. In addition, this serologic pattern has been associated with significantly lower circulating HBsAg levels, indicating a potentially distinct virological or immunological phenotype [13]. These findings suggest that this serologic pattern is uncommon overall but may be more frequently observed in regions with high HBV endemicity, likely reflecting differences in HBV genotypes, host immunity, vaccination coverage, and diagnostic methodologies. Data on racial and ethnic predisposition remain limited, but available studies indicate higher reporting rates in Asian and Mediterranean populations, consistent with regional HBV epidemiology [9], from a clinical and public health perspective, these findings are important. They underscore the continued importance of hepatitis B vaccination programs, especially in regions with high endemicity, as vaccination remains the most effective strategy for preventing HBV transmission and reducing the overall burden of disease. Careful assessment of vaccination history and comprehensive serologic testing are therefore essential to ensure accurate diagnosis and optimal patient management. Several pathogenic and immunologic mechanisms have been proposed to account for this serologic phenomenon. One of the most widely accepted explanations involves Immune Escape Mutations within the “a” determinant region of the HBV surface (S) gene—most notably the G145R mutation—can alter the antigenic structure of HBsAg, reducing recognition by anti-HBs antibodies [4, 5]. These immune escape variants have been well documented in patients with chronic HBV infection, including those with vaccine breakthrough infections or prior antiviral therapy. In previously reported cases, genotypic analysis has frequently identified such mutations; however, HBV genotyping was not performed in our patient, representing a notable limitation of this case. Another proposed mechanism relates to viral heterogeneity and host immune factors. Superinfection with a heterologous HBV subtype may result in the production of anti-HBs antibodies directed against one serotype, although a different circulating HBsAg subtype persists unchecked. In this scenario, the generated antibodies fail to effectively neutralize non-homologous HBsAg, allowing continued viral replication despite apparent serologic immunity [14]. Age-related viral evolution may also contribute to this phenomenon. Several studies have demonstrated that amino acid substitutions within the HBV genome accumulate over time and are more frequently observed in older individuals [9, 10]. This progressive viral variability may facilitate immune escape and increase the likelihood of concurrent HBsAg and anti-HBs positivity, which may partially explain the observed serologic pattern in our 60-year-old patient. In the present case, the patient demonstrated reactive HBsAg, total anti-HBc, and anti-HBs positivity, with low level but detectable HBV DNA levels, confirming chronic HBV infection despite the presence of anti-HBs. Previous studies by Wang et al. [6], Zhang et al. [15] have shown that the anti-HBs positivity is often associated with lower HBsAg levels, this is consistent with our findings. Furthermore, Jin et al. [7] reported that patients with low-level HBsAg and concurrent anti-HBs carry an increased risk of HCC when compared with those lacking anti-HBs, underscoring the clinical relevance of quantifying these markers. Although long-term outcome data for our patient are limited, these findings underscore the risk of diagnostic misinterpretation and false reassurance if HBV serologic markers are interpreted in isolation. This case adds to the existing literature by demonstrating how an atypical serologic pattern can be incidentally identified during routine pre-procedural screening in a primary care settings, where it carries a substantial risk of misinterpretation and delayed diagnosis. The finding highlights a common clinical scenario in primary care and underscores the importance of routine screening even in asymptomatic individuals. Notably, the patient had no history of recognized high-risk exposures, including blood transfusion, intravenous drug use, or household contact with hepatitis B virus, emphasizing that chronic infection may remain clinically silent and undetected in the absence of systematic testing. From a clinical standpoint, low-level viremia, as documented by HBV DNA above the assay detection limit (20 IU/mL), warrants regular monitoring, including liver function tests and imaging for early detection of disease progression. Short-term follow-up at 4 months demonstrated biochemical and radiologic stability with normal transaminases, normal alpha-fetoprotein levels, and an unremarkable abdominal ultrasound. Although reassuring, this does not exclude long-term risk, and continued surveillance remains essential. In cases with atypical serologic patterns, HBV genotyping may provide additional prognostic information, particularly regarding potential immune escape mutations and long-term hepatocellular carcinoma risk. Taken together, this case highlights an important clinical principle: the presence of anti-HBs alone should not be assumed to indicate viral eradication or vaccination. Accurate serologic interpretation requires integration of virologic data, particularly in the presence of detectable HBsAg or HBV DNA. Comprehensive evaluation, including HBV DNA quantification and fibrosis assessment, is essential to accurately characterize disease status, prevent false reassurance, and guide appropriate clinical management. For primary care physicians, awareness of this rare serologic profile and the importance of routine pre-procedural HBV screening, can uncover unexpected chronic infections even in asymptomatic patient without known risk factors which helps ensure timely referral and appropriate longitudinal follow-up. Study limitations This case has several limitations. First, HBV genotyping and mutation analysis were not performed, limiting our ability to confirm immune escape mutations. Second, the evaluation was based on a single time point, with no longitudinal follow-up. Serial monitoring of HBV DNA, HBsAg, and anti-HBs levels would be valuable to assess disease evolution, serologic changes, and long-term outcomes. Future studies could address these gaps. Clinical implications Clinicians should be aware of the diagnostic pitfall posed by concurrent HBsAg and anti-HBs positivity, as this serologic pattern does not exclude chronic hepatitis B infection. Evaluation should include HBV DNA quantification and assessment of hepatic fibrosis, with referral to a specialist for appropriate risk stratification and longitudinal monitoring. In patients with atypical serologic profiles, HBV genotyping may provide additional prognostic information, particularly regarding immune escape mutations and long-term hepatocellular carcinoma risk. Routine hepatitis B screening prior to invasive procedures remains essential, as it may identify previously unrecognized chronic infection in asymptomatic individuals without identifiable high-risk exposures. Conclusion This case illustrates a rare and clinically important serologic pattern of coexisting HBsAg and anti-HBs positivity in a patient with chronic hepatitis B infection, identified incidentally during routine screening and in the absence of prior vaccination or known risk factors. Anti-HBs positivity should not be assumed to indicate viral clearance or vaccination, and atypical serologic profiles require integration of serologic, virologic, and clinical data for accurate diagnosis and risk stratification. Routine hepatitis B screening prior to invasive procedures may uncover previously unrecognized chronic infection, allowing timely monitoring and preventive strategies. Clinicians should remain vigilant for such atypical presentations, as they carry important implications for long-term disease surveillance, therapeutic decision-making, and hepatocellular carcinoma risk. Specialist referral, comprehensive virologic assessment, and ongoing surveillance, including consideration of HBV genotyping, areessential to optimize patient management. Acknowledgements Not applicable. Abbreviations Hepatitis B virus Hepatocellular carcinoma Hepatitis surface antigen Anti hepatitis B surface antigen antibodies Anti hepatitis B surface antigen antibodies Chronic hepatitis B Fecal immunochemical testing HBV deoxyribonucleic acid Hepatitis C virus antibodies HBV core immunoglobulin M HBV core total antibodies Reference range HBV DNA polymerase chain reaction Aspartate aminotransferase Alanine aminotransferase Liver function tests Ultrasound Common bile duct Portal vein Intra hepatic biliary duct Controlled attenuation parameter Interquartile range Hepatitis B e antigen Author contributions GB, MB, HM analyzed and interpreted the patient data regarding the virology. EH, MM, AS analyzed and interpreted the patient data regarding the chemistry, GB major contributor in writing the manuscript. AY, GB Accounted for the idea and collected the data. All authors read and approved the final manuscript. Funding Not applicable. Data availability The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate Ethical approval for the publication of this case report was obtained from the Institutional Review Board (IRB) of King Khaled Hospital, Ministry of Health, Najran, Saudi Arabia (IRB Approval No.: [Log Oct 2025-72A]). The report was prepared in accordance with institutional guidelines and the principles of the National committee of Bioethics (NCBE). A copy of the written consent is available for review by the Editors of this journal. Consent for publication Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. Competing interests The authors declare that there are no competing interests regarding the publication of this article. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.